AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

AI-powered chatbots will enhance HCP engagement, while comprehensive customer lifetime value prediction will enable more ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

The Life Sciences Industry Report: Trends & Predictions 2025 is built for those who are serious about growth, innovation, and ...

Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

This 18th-20th February, 2025, London will host the premier HR event for European Life Sciences. Join CHROs, CPOs, and HR ...

From consumer products to clinical trials, anything that is designed without input from its intended recipients will likely feel disconnected from their needs. Conversely, systemically gathering their ...